Albuquerque, New Mexico--(Newsfile Corp. - February 20, 2023) - DXD Capital, a data-driven real estate and private equity firm based in Albuquerque, NM, is seeking to capitalize on the strong ...
New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...
SAN ANTONIO -- Results from two randomized phase III trials supported the use of trastuzumab deruxtecan (T-DXd; Enhertu) as a second- or third-line standard of care in patients with metastatic ...
When Merck & Co. and Daiichi Sankyo last year received an FDA complete response letter for their HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan, the companies hoped to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback